We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

50 hedge funds and large institutions have $86.6M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

18% more capital invested

Capital invested by funds: $73.3M → $86.6M (+$13.3M)

9% more funds holding

Funds holding: 46 → 50 (+4)

Holders
50
Holders Change
+4
Holders Change %
+8.7%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$4.89M
2
PC
Periscope Capital
Ontario, Canada
+$3.32M
3
GCL
Glazer Capital LLC
New York
+$2.83M
4
FTCM
First Trust Capital Management
Illinois
+$2.26M
5
MF
Magnetar Financial
Illinois
+$1.3M

Top Sellers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
-$2.94M
2
GCM
Ghisallo Capital Management
Massachusetts
-$1.97K
3
CSS
Cubist Systematic Strategies
Connecticut
-$197
4
RCM
Radcliffe Capital Management
Pennsylvania
-$10
Name Holding Trade Value Shares
Change 		Change in
Stake
Calamos Advisors
26
Calamos Advisors
Illinois
$992K +$987K +100,000 New
TCM
27
Tenor Capital Management
New York
$991K – – –
CCM
28
CAAS Capital Management
New York
$958K – – –
GF
29
Gabelli Funds
New York
$726K – – –
GCIA
30
Gabelli & Co Investment Advisers
New York
$650K – – –
CSS
31
Cubist Systematic Strategies
Connecticut
$600K -$197 -20 -0%
WA
32
Whitebox Advisors
Minnesota
$500K – – –
PAMP
33
Polar Asset Management Partners
Ontario, Canada
$461K – – –
TCA
34
Taconic Capital Advisors
New York
$461K – – –
ACM
35
Atalaya Capital Management
New York
$397K – – –
AGC
36
Angelo Gordon & Co
New York
$396K – – –
ETH
37
Exos TFP Holdings
New York
$357K +$356K +36,044 New
OAC
38
OMERS Administration Corp
Ontario, Canada
$347K – – –
VI
39
Vestcor Inc
New Brunswick, Canada
$347K – – –
WRBC
40
W.R. Berkley Corp
Connecticut
$195K – – –
DIG
41
DeepCurrents Investment Group
New York
$176K – – –
SCM
42
Saba Capital Management
New York
$171K – – –
SSA
43
Schonfeld Strategic Advisors
New York
$141K – – –
LCM
44
Landscape Capital Management
New Jersey
$109K – – –
AA
45
Ancora Advisors
Ohio
$69K – – –
ACA
46
Arena Capital Advisors
California
$57K – – –
UBS Group
47
UBS Group
Switzerland
$15K – – –
EC
48
Elequin Capital
New York
$3K +$2.96K +300 New
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
$271 +$270K +27,325 New
SCM
50
Suvretta Capital Management
New York
– -$2.94M -300,000 Closed
1
2
3

EBAC Hedge Fund Activity: Q3 2022 in Review

50 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q3 2022, worth a combined $86.6M — up 18% from $73.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new EBAC positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $4.89M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $2.94M sold.

  • 50 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q3 2022, up from 46 in Q2 2022.
  • Funds reported $86.6M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q3 2022, up 18% quarter-over-quarter.
  • 7 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q3 2022 and 2 closed out, a net change of +5 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $4.89M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q3 2022 was Suvretta Capital Management, an estimated $2.94M sold.

Based on aggregated 13F filings for Q3 2022.